AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 231 min read$CBIO

Lynch Ryan sold $8K of CBIO

Lynch Ryan (See Remarks) sold 465 shares of CRESCENT BIOPHARMA, INC. (CBIO) at $17.99 on 2026-06-22 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Lynch Ryan
Published Jun 23, 2026, 8:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 23, 2026, 8:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CBIO
Neutral
medium confidence
Mentioned
$CBIO
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CBIONeutralLow
01

Why it matters

A single small-to-moderate insider sale under a pre-arranged 10b5-1 plan typically has limited informational content versus unscheduled sales or other fundamental disclosures.

02

Market read

Traders may note the sale for sentiment monitoring, but it is unlikely to drive a new fundamental repricing.

03

What to watch

The filing does not state any change in business outlook, guidance, or risk factors; without those, trading impact should be limited.

Relevance 2/10Novelty 3/10Timing: post-filing disclosure (filed 2026-06-23) of a 2026-06-22 insider sale

Background

The article is an SEC Form 4 insider transaction disclosure for Crescent Biopharma, Inc. (CBIO).

Company-level read

Ticker impact

$CBIONeutralMedium confidence
Context

SEC Form 4 shows officer Lynch Ryan sold 465 CBIO shares on 2026-06-22 at $17.99 via a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a disclosed open-market sale under a pre-arranged Rule 10b5-1 plan, with no accompanying new operational/regulatory/financial information.

Market effects

Sector

None; this is company-specific insider transaction disclosure.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.

Key entities

  • issuer
    Crescent Biopharma, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Lynch Ryan

    Officer who sold 465 shares on 2026-06-22 at $17.9900/share.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CBIO insider trading history →

Related articles

OCT 19
$CBIOMed

H.C. Wainwright reiterates Crescent Biopharma stock rating at buy

H.C. Wainwright reiterated a Buy rating and $36.00 price target on Crescent Biopharma (CBIO), citing progress in mid-stage clinical trials for its CR-001 drug. The stock trades at $11.84, with potential upside of over 200%. Crescent announced completion of dose escalation in its ASCEND trial and enrollment of over 125 patients. The company aims to dose over 2,000 patients by mid-2027 and start Phase 3 trials in early 2028.

investing.com2 min
OCT 16
$CBIOHighAI 8/10

Stifel reiterates Crescent Biopharma stock rating on pipeline progress

Stifel maintained a Buy rating and $28.00 price target for Crescent Biopharma (CBIO) after its pipeline update, noting progress in trials and patient dosing. The stock, trading at $12.48, has dropped 16% in a week. Crescent recently raised $143.7M via a public offering, with H.C. Wainwright upgrading its rating to Buy with a $36.00 target. The company's enterprise value is below $500M, and it expects to dose over 2,000 patients by mid-2027.

investing.com2 min
OCT 15
$CBIOMed

Crescent Biopharma advances CR-001 combos, clears IND for CR-002 and sets mid‑2027 data timelines

Crescent Biopharma (CBIO) announced enrollment in CR-001 chemo combination cohorts and IND allowance for CR-002, with initial data expected in 2027. The company completed CR-001 monotherapy dose escalation and expects initial monotherapy data from over 125 patients and ORR in up to 12 1L NSCLC patients by Q1 2027. The FDA allowed IND for CR-002, with a global Phase 1/2 APOLLO trial to start Q4 2026 and initial data anticipated in H2 2027.

tradingview.com1 min
OCT 15
$CBIOMed

Crescent Biopharma, Inc. issued a press release announcing clinical pipeline updates, including (i) enrolling patients in cohorts combining CR-001, a PD-1 x…

CRESCENT BIOPHARMA, INC. (CBIO) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On October 15, 2026, Crescent Biopharma, Inc. (“Crescent” or the “Company”) issued a press release announcing clinical pipeline updates, including (i) enrolling patients in cohorts combining CR-001, a PD-1 x VEGF bispecific antibody, plus standard of care

SEC EDGAR 8-K4 min
OCT 6
$CBIOHigh

Crescent Biopharma stock rating upgraded to buy at H.C. Wainwright

H.C. Wainwright upgraded Crescent Biopharma (CBIO) to Buy with a $36.00 price target, citing potential catalysts in 2027. The stock is currently trading at $13.94. The firm highlighted the company's antibody-drug conjugate pipeline and recent public offering raising $143.7 million. CBIO's balance sheet shows more cash than debt, a strength for a clinical-stage biotech.

investing.com2 min